Magnus Tobiasson group - Biological and clinical aspects of the myelodysplastic syndrome

The Magnus Tobiasson research group is studying biological and clinical aspects of the myelodysplastic syndrome (MDS).

About our research

The main focus of the group is to implement new genetic tools in the management of patients with MDS during the transplantation process. Magnus Tobiasson is coordinating the Nordic MDS group study NMDSG14B. The research is aimed at developing and evaluating individual minimal residual disease (MRD) markers for early detection of relapse after allogeneic stem cell transplantation. The study has generated several spin-off projects such as evaluation of MRD on sorted stem and progenitor cells, and evaluation of the importance of achieving clonal reduction prior to transplantation. 

Group leader

Magnus Tobiasson

Affiliated to research
H7 Department of Medicine, Huddinge

Magnus Tobiasson is MD, PhD, a clinical hematologist and a translational researcher within the field of myelodysplastic syndrome and other myeloid malignancies.

Group members

Carolin Lindholm

PhD Student
H7 Department of Medicine, Huddinge

Carolin Lindholm joined the group as PhD student in 2019. She studied medicine at Karolinska Institutet, and is currently working as a resident doctor in hematology at Karolinska University hospital. Her research focus is in myelodysplastic syndromes, mainly on the transplantation process and MRD markers.

Joel Wiggh became a PhD student in September 2020. He is a resident doctor in Hematology at the Karolinska Universital Hospital in Huddinge.

The aim of Joel's research at MedH is to increase the knowledge on how a patient’s unique genetic profile can be used to guide treatment before allogenic stem cell transplantation. The overall goal is to implement individualized pre-transplantation treatment for patients with Myelodysplastic Syndrome and consequently improve their prognosis.    

Research support

  • Tobias Stiftelsen
  • Strategic research area (SRA) in stem cells and regenerative medicine
  • Region Stockholm (SLL)
  • Centrum för innovativ medicin (CIMED) 

Publications

  1. Absence of a common founder mutation in patients with cooccurring myelodysplastic syndrome and plasma cell disorder.
    Klimkowska M, Nannya Y, Gran C, Månsson R, Douagi I, Ogawa S, Nahi H, Tobiasson M Blood 2021 Mar;137(9):1260-1263
     
  2. Multicenter Next-Generation Sequencing Studies between Theory and Practice: Harmonization of Data Analysis Using Real-World Myelodysplastic Syndrome Data.
    Sandmann S, de Graaf AO, Tobiasson M, Kosmider O, Abáigar M, Clappier E, Gallì A, van der Reijden BA, Malcovati L, Fenaux P, Díez-Campelo M, Fontenay M, Hellström-Lindberg E, Jansen JH, Dugas M. J Mol Diagn 2021 Mar;23(3):347-357
     
  3. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.
    Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, Yoshizato T, Shiozawa Y, Saiki R, Malcovati L, Levine MF, Arango JE, Zhou Y, Solé F, Cargo CA, Haase D, Creignou M, Germing U, Zhang Y, Gundem G, Sarian A, van de Loosdrecht AA, Jädersten M, Tobiasson M, Kosmider O, Follo MY, Thol F, Pinheiro RF, Santini V, Kotsianidis I, Boultwood J, Santos FPS, Schanz J, Kasahara S, Ishikawa T, Tsurumi H, Takaori-Kondo A, Kiguchi T, Polprasert C, Bennett JM, Klimek VM, Savona MR, Belickova M, Ganster C, Palomo L, Sanz G, Ades L, Della Porta MG, Elias HK, Smith AG, Werner Y, Patel M, Viale A, Vanness K, Neuberg DS, Stevenson KE, Menghrajani K, Bolton KL, Fenaux P, Pellagatti A, Platzbecker U, Heuser M, Valent P, Chiba S, Miyazaki Y, Finelli C, Voso MT, Shih LY, Fontenay M, Jansen JH, Cervera J, Atsuta Y, Gattermann N, Ebert BL, Bejar R, Greenberg PL, Cazzola M, Hellström-Lindberg E, Ogawa S, Papaemmanuil E Nat Med 2020 10;26(10):1549-1556
     
  4. Myelodysplastic syndromes: moving towards personalized management.
    Hellström-Lindberg E, Tobiasson M, Greenberg P. Haematologica 2020 07;105(7):1765-1779
     
  5. Angioimmunoblastic T-cell lymphoma and myelodysplastic syndrome with mutations in TET2, DNMT3 and CUX1 - azacitidine induces only lymphoma remission.
    Tobiasson M, Pandzic T, Cavelier L, Sander B, Wahlin BE. Leuk Lymphoma 2019 12;60(13):3316-3319
     
  6. Treatment of myelodysplastic syndrome in the era of next-generation sequencing.
    Tobiasson M, Kittang AO. J Intern Med 2019 07;286(1):41-62
     
  7. Male sex and the pattern of recurrent myeloid mutations are strong independent predictors of blood transfusion intensity in patients with myelodysplastic syndromes.
    Rydén J, Edgren G, Karimi M, Walldin G, Tobiasson M, Wikman A, Hellström-Lindberg E, Höglund P. Leukemia 2019 02;33(2):522-527
     
  8. Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies.
    Komrokji R, Swern AS, Grinblatt D, Lyons RM, Tobiasson M, Silverman LR, Sayar H, Vij R, Fliss A, Tu N, Sugrue MM. Oncologist 2018 02;23(2):159-170
     
  9. SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells.
    Mortera-Blanco T, Dimitriou M, Woll PS, Karimi M, Elvarsdottir E, Conte S, Tobiasson M, Jansson M, Douagi I, Moarii M, Saft L, Papaemmanuil E, Jacobsen SEW, Hellström-Lindberg E Blood 2017 08;130(7):881-890
     
  10. Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes.
    Unnikrishnan A, Papaemmanuil E, Beck D, Deshpande NP, Verma A, Kumari A, Woll PS, Richards LA, Knezevic K, Chandrakanthan V, Thoms JAI, Tursky ML, Huang Y, Ali Z, Olivier J, Galbraith S, Kulasekararaj AG, Tobiasson M, Karimi M, Pellagatti A, Wilson SR, Lindeman R, Young B, Ramakrishna R, Arthur C, Stark R, Crispin P, Curnow J, Warburton P, Roncolato F, Boultwood J, Lynch K, Jacobsen SEW, Mufti GJ, Hellström-Lindberg E, Wilkins MR, MacKenzie KL, Wong JWH, Campbell PJ, Pimanda JE. Cell Rep 2017 07;20(3):572-585
     
  11. Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease.
    Tobiasson M, Abdulkadir H, Lennartsson A, Katayama S, Marabita F, De Paepe A, Karimi M, Krjutskov K, Einarsdottir E, Grövdal M, Jansson M, Ben Azenkoud A, Corddedu L, Lehmann S, Ekwall K, Kere J, Hellström-Lindberg E, Ungerstedt J. Oncotarget 2017 Apr;8(17):28812-28825
     
  12. Mutations in histone modulators are associated with prolonged survival during azacitidine therapy.
    Tobiasson M, McLornan DP, Karimi M, Dimitriou M, Jansson M, Ben Azenkoud A, Jädersten M, Lindberg G, Abdulkadir H, Kulasekararaj A, Ungerstedt J, Lennartsson A, Ekwall K, Mufti GJ, Hellström-Lindberg E. Oncotarget 2016 Apr;7(16):22103-15
     
  13. Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial.
    Tobiasson M, Dybedahl I, Holm MS, Karimi M, Brandefors L, Garelius H, Grövdal M, Högh-Dufva I, Grønbæk K, Jansson M, Marcher C, Nilsson L, Kittang AO, Porwit A, Saft L, Möllgård L, Hellström-Lindberg E. Blood Cancer J 2014 Mar;4(3):e189
     
  14. High prevalence of restless legs syndrome among patients with polycytemia vera treated with venesectio.
    Tobiasson M, Alyass B, Söderlund S, Birgegård G. Med Oncol 2010 Mar;27(1):105-7